Synergia Medical is pleased to announce that they have been awarded the Prix Galien 2023 in Belgium for promising medical devices.
Synergia Medical today announced the successful completion of an additional €3.8 million of Series B funding bringing the total to €12.8 million. This allows Synergia Medical to prepare for First-In-Human clinical trials planned for 2024.
Synergia Medical announced the appointment of Dan Scherrer as Chief Operating Officer. Dan Scherrer brings over 20 years of experience manufacturing, supply chain, quality management and product development in the medical device field.
Synergia Medical announced that it has been awarded a €2.5 million grant from the EIC Accelerator program with the potential for an equity investment from the EU in the future Series C fund raising of a further €7.5 million.
Synergia Medical announced the successful completion of a €9 million Series B funding round. This allows Synergia Medical to prepare for First-In-Human clinical trials planned for 2023 and the IDE (Investigational Device Exemption) submission to the FDA in the USA. IDE allows an investigational device to be used in a clinical study to collect safety and efficacy data.
Synergia Medical is proud to announce the renewal of its ISO 13485 – Medical Devices – Quality Management System certification.
Synergia Medical is pleased to welcome Denis Gestin to its Board of Directors.
Synergia Medical is proud to have been selected as one of the 5 finalists of the 9th Annual Shark Tank Competition organized by the Epilepsy Foundation.
We are very proud to announce that we have been selected for the MedTech Innovator Annual Accelerator and Showcase program.
Synergia Medical proudly announces the appointment of Mrs. Sophie Baratte as Chair of the Board.
Synergia Medical just obtained its first patent in the United States for its optical energy neurostimulator.
Yves Jongen, currently board member of Synergia Medical, succeeds Reinhard Krickl and becomes Chairman ad interim.
We are proud to share that our versatile neurostimulation technological platform will enjoy the support of Horizon 2020.
For the last couple of months the Accenture Innovation Awards (AIA) has brought us on a journey. Hereby we are proud to announce that our recent work has made it to the Top 25 Health innovators in the AIA competition!
We are proud to announce our team's growth with our tenth employee! Welcome to her.
Synergia Medical was selected to be part of the 20 most promising European HealthTech companies.
Presentation pitch was held in front of lead European MedTech investors in Lausanne, Switzerland.
We are very pleased to announce that Yves Jongen and Jacques van Rijckevorsel have joined Synergia Medical's Board of directors.
Our patent "Photovoltaic Electrical Stimulation Device" has been granted by the European Patent Office.
Wim Goemaere joins as new Board member, bringing an impressive financial background.
1,1 million € of non-dillutive capital granted by the Walloon Region for our NEUROPV project.
The first working prototype is completed and demonstrated to the company's shareholders.
A seed round of 2,5 mio € is closed with private investors.
In less than 12 months, DEKRA notified body grants the company quality system with the ISO 13485 certification.
The company is happy to announce its first round of private investors composed by 3F's
Our first proof of concept using PV cells is gone out of the lab and is working. Congrats to the dev team!
In september 2014 our first two employees joined the team. Real work can now start!
VitalSyn and OptiStart R&D projects are financed by Région Wallonne's DGO6
After 6 months of maturation, Pascal Doguet and Attila Borbath founded Synergia Medical on September 26th, 2013
The Synergia Medical team was delighted to display 4 scientific posters at INS Barcelona 2022.
